Glucose Metabolism in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers, with a five-year survival rate of around 5% to 8%. To date, very few available drugs have been successfully used to treat PDAC due to the poor understanding of the tumor-specific features. One of the hallmarks...
Main Authors: | Liang Yan, Priyank Raj, Wantong Yao, Haoqiang Ying |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/10/1460 |
Similar Items
-
Regulating Glucose Metabolism with Prodrug Nanoparticles for Promoting Photoimmunotherapy of Pancreatic Cancer
by: Fang Sun, et al.
Published: (2021-02-01) -
Prevalence of hypertension, levels of lipids and blood glucose in patients with acute pancreatitis, chronic pancreatitis and pancreatic cancer
by: I. N. Grigorieva, et al.
Published: (2020-07-01) -
Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase
by: Neha Sharma, et al.
Published: (2020-09-01) -
Association between fasting blood glucose levels at admission and overall survival of patients with pancreatic cancer
by: Mingming Zhang, et al.
Published: (2021-02-01) -
Metabolic Dependencies in Pancreatic Cancer
by: Ali Vaziri-Gohar, et al.
Published: (2018-12-01)